Meeting
2023 ASCO Annual Meeting
Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).
Authors
Mamta Parikh
University of California Davis Comprehensive Cancer Center, Sacramento, CA
Mamta Parikh , Catherine Tangen , Maha H. A. Hussain , Shilpa Gupta , Yeonjung Jo , Andrea Harzstark , Channing Judith Paller , Saby George , Matthew R. Zibelman , Heather H. Cheng , Benjamin L. Maughan , Jingsong Zhang , Russell Kent Pachynski , Alan Haruo Bryce , Daniel W. Lin , David I. Quinn , Ian M Thompson Jr., Tanya B. Dorff , Primo N Lara Jr., Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Clinical Trial Registration Number
NCT01809691
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5074)
DOI
10.1200/JCO.2023.41.16_suppl.5074
Abstract #
5074
Poster Bd #
168
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.
First Author: Amir Goldkorn
Poster
2023 ASCO Annual Meeting
Outcomes of Black (B) versus White (W) patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (Ort): Analysis of pt-level data from SWOG-1216 phase 3 trial.
First Author: Nicolas Sayegh
Poster
2022 ASCO Annual Meeting
Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial.
First Author: Fred Saad
Poster
2020 ASCO Virtual Scientific Program
Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.
First Author: Primo Lara Jr.